US Melanoma Market Share And Trends Analysis By Type (Superficial Spreading, Nodular, Lentigo Maglina, Acral Lentigious), Gender (Male And Female), Treatment (Immunotherapy, Biologic Therapy, Radiation Therapy, Chemotherapy, Surgery), Diagnosis (Abcde, Ugly Duckling, Biopsy), End Users (Hospitals, Pharmaceutical Companies, Research Centers, Clinics, Laboratories) – Global Forecast to 2023
The US Melanoma Market Size is projected to achieve USD 3.2 billion at a 8.3% CAGR during the forecast period. Cancer types are becoming increasingly malignant and becoming more prevalent one of which are melanomas. Market reports connected with the healthcare industry have been made available by Market Research Future which generates reports on other business verticals that outlines the current market scenarios.
The increasing prevalence of factors that because melanomas is raising the focus on the development of the market. Increasing exposure to ultraviolet light especially in tanning beds is considered the main cause for the rise in the expansion of the market. The development of relatively effective treatment courses and rising research and development into the treatment of melanomas is anticipated to accelerate the development of the market in the US region in the duration of the forecast period.
Request Free Sample Report at: https://www.marketresearchfuture.com/sample_request/2950
US Melanoma Market Segmental Analysis
The segmentation of the US melanoma market has been segmented based on type into superficial spreading, lentigo maglina, nodular, acral lentigious and others. Based on gender, the market is segmented into female and male. Based on treatment, the US melanoma market is segmented into chemotherapy, immunotherapy, radiation therapy, biologic therapy, surgery among others. The segmentation based on diagnosis, comprises of ugly duckling, ABCDE, biopsy, and others. The end user-based segmentation of the market comprises of pharmaceutical companies, clinics, hospitals, research center, and laboratories.
US Melanoma Market Detailed Regional Analysis
The melanoma market in the US is studied across states such as Georgia, New Jersey, North Carolina, New York, Illinois, Ohio, Florida, Washington, Pennsylvania, Texas, California, Virginia and Rest of US. The Californian state is responsible for the major market for melanoma in US followed by states such as Ohio and Florida. California and Florida are important regions for the melanoma market as many melanoma cases are found in this region. New York is the third major market after Florida. The number of skin cancer patients is mounting progressively in states such as Texas and Florida. This is owing to their exposure to ultraviolet rays and widespread use of tanning beds in these regions. The technological advancement in the field of treatment and diagnosis of melanoma in the US also drives this market.
US Melanoma Market Competitive Analysis
Improved accessibility to diverse resources and capabilities is expected to impel the growth of the market in the coming forecast period. The use of effective strategy execution techniques is anticipated to bear positively on the future growth of the market. Furthermore, the vertical integrations and product strategies of the market is increasing the potential for the market players. The competitors in the market are attempting to establish various leaderships that will enable them to capture a more significant share of the market. Product differentiation has created a favorable product differentiation scenario that is complementing the market’s growth. The analysis of the market reveals that it is poised for a high growth rate in the forthcoming years.
The significant players shaping the US melanoma industry are Bristol-Myers Squibb, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Amgen Inc., Genentech Inc., Janssen Biotech, Inc., Pfizer, Novartis International AG, Vical and Ziopharm.
Intended Audience
- Hospitals
- Pharmaceutical companies
- Research and development (R&D) companies
- Academic medical institutes and universities
- Melanoma drug manufactures
- Melanoma drug suppliers
Table of Contents:
1 Report Prologue
2 US Melanoma Market Introduction
2.1 Introduction
2.2 Scope Of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 US Melanoma Market Dynamics
4.1 Drivers
4.1.1 Increasing Awareness Regarding Skin Cancer
4.1.2 Increased Emphasis On Early Detection Of Cancer
4.1.3 Increasing Inclination Towards Preventive Care
4.2 Restrains
4.2.1 Risk Associated With Blood Transfusion
5 US Melanoma Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Supply Chain Analysis
6 US Melanoma Market, By Type
6.1 Superficial Melanoma
6.2 Nodular Melanoma
6.3 Lentigo Maglina Melanoma
6.4 Acral Lentigious
6.5 Others
7 US Melanoma Market, By Gender
7.1 Male
7.2 Female
8 US Melanoma Market, By Treatment
8.1 Immunotherapy
8.2 Biological Therapy
8.3 Radiation
8.4 Chemotherapy
8.5 Surgery
8.6 Others
9 US Melanoma Market, By Diagnosis
9.1 ABCDE
9.2 Ugly Duckling
9.3 Biopsy
9.4 Others
10 US Melanoma Market, By End User
10.1 Hospitals
10.2 Pharmaceutical Companies
10.3 Research Centers
10.4 Clinics
10.5 Laboratories
11 Competitive Landscape
11.1 Pricing Of Drugs For Melanoma
11.2 Production Capacity Of Major Players
12 Company Profile
13 Bibliography
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
